By targeting toxic protein clumps in the brain, Dr. Martin Tolar, founder-CEO of Alzheon, aims to outsmart Alzheimer’s decades ahead of symptoms – and reshape global neurology.
Dr. Adil Ali
– 5 min read
Speaking of innovation, AI is a hot topic. Is that a consideration for you?
Absolutely. My background is in computer science, and I have founded a few companies in AI. One of them is Tolion Health, which is focused on applying AI to develop personalized, predictive and preventive medicine with lifestyle recommendations for improving and maintaining brain health. The idea is that lots of medical knowledge isn’t readily accessible to practitioners or patients and a personal health coach can have a tremendous impact on health, quality of life and longevity. AI can help process vast amounts of data to provide personalized health insights based on genetics, family history, and medical status.
In drug development, AI can assist in understanding protein structures, predicting outcomes, and repositioning existing drugs. We saw recently that a Nobel Prize was awarded for work in AI that helps understand protein folding, which is invaluable in our field.